See the full story in the original article.
Read the original on Yahoo Finance ↗
Keywords
Pfizerearningspharmaceuticalshealthcare
Open a keyword to see other news on the same topic.
Related news
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
Biotech stocks rose last week and beat the broader market, with IBB up 5%, XBI up 4% and XLV up 3%, while SPY fell 0.6% and QQQ dropped 2%. This week, Vertex reports on Monday after the close, with second-quarter sales of $49.6 million for Journavx and $76.4 million for Casgevy. Pfizer (PFE) and Amgen (AMGN) report on Tuesday, Novo Nordisk (NVO) on Wednesday, and Moderna (MRNA) on Friday. Investors will watch Wegovy pill sales, whether Pfizer's newer medicines can offset weaker COVID-related sales, and updates on Amgen's MariTide and Moderna's personalized cancer vaccine. Cancer research will also be presented at the Society for Immunotherapy of Cancer's annual meeting, running November 4 to 8 in Phoenix.
- Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna shares fell 10% to $214.03 in morning trading as investors took profits after a steep rally tied to its personalized cancer vaccine. In August, Moderna said intismeran autogene, given with Keytruda, met its primary endpoint in a late-stage melanoma trial, sending the stock to its best single-day gain ever. Five-year follow-up from a Phase 2b study showed the combination cut the risk of recurrence or death by 49% versus Keytruda alone. Meanwhile, BioNTech fell 2%, Pfizer rose 0.3%, the iShares Biotechnology ETF slid 2% and the S&P 500 ETF (SPY) dipped 0.1%, pointing to selling concentrated in Moderna. Goldman Sachs raised its price target but kept a Neutral rating, with full melanoma data due at ESMO later this month.
- Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction
Pfizer reported flat third-quarter revenue of $16.6 billion and raised its full-year outlook, with revenue guidance now $62.0 billion to $64.0 billion and adjusted EPS guidance $2.95 to $3.05. Eliquis rose 25% year over year to $2.52 billion, beating roughly $2.40 billion expected and offsetting lower COVID and Prevnar sales, with higher U.S. net price cited as a key driver. Reported diluted EPS fell to $0.56 from $0.62, while adjusted diluted EPS held at $0.87. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally. The article notes that price-driven gains can be harder to repeat than demand-driven ones, especially with the Medicare negotiated price in effect for 2026.
- Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally?
Pfizer (PFE) reported third-quarter revenue of $16.6 billion, above the $15.9 billion analyst expectation, and adjusted EPS of $0.87 versus $0.73 estimates. It raised full-year adjusted EPS guidance to $2.95 to $3.05 from a prior $2.80 to $3, and expects savings of about $9.7 billion through 2029. Revenue from launched and acquired products rose 32% in the quarter, while the company generates less revenue from COVID products than in the past. The article argues the stock is undervalued, with a forward P/E of about 10 and a dividend yield of 5.6%, even though it is up more than 20% this year and still down more than 30% over five years.
- Pfizer hikes full-year outlook, taps company veteran as new CFO
Pfizer reported third-quarter adjusted earnings of 87 cents per share versus 73 cents expected and revenue of $16.58 billion versus $15.87 billion expected, and it raised its full-year outlook, citing strong year-to-date performance and ongoing cost cuts. Full-year revenue guidance rose to $62 billion to $64 billion from $60.5 billion to $62.5 billion, and adjusted EPS guidance rose to $2.95 to $3.05 per share from $2.80 to $3. Cecile Guegan, who has held various finance roles at the company over two decades, became chief financial officer this month after serving as interim CFO since August, when Dave Denton left to become CFO at Nike.
- Apple, Palantir, Pfizer, Marvell, AMD, Bloom Energy, Gartner, and More Stocks That Explain Today’s Market
Apple shares fall after the iPhone maker’s guidance fails to meet investors’ high bar.
Related markets
Latest news
- Asian Stocks Slump, Nikkei Loses Over 2,200 Points as US Development Reverses Market
Asian stock markets fell sharply on the morning of 4 November as US midterm election vote counting began, with early results suggesting the Democrats could win control of the House and were leading in some Senate races. Japan's Nikkei 225 at one point dropped more than 2,200 points, or 3.6%, with chip-memory maker Kioxia Holdings falling more than 11%, while South Korea's KOSPI slipped more than 3% and Taiwan's Taiex fell nearly 1%. Investors are concerned that a Democratic-led Congress may be less supportive of data-centre construction than Republicans under President Donald Trump, after the Nasdaq rose 0.8% and the Philadelphia Semiconductor Index (SOX) gained 2.6% on Wall Street in the previous session. The US dollar also weakened against the yen, falling from above 158 yen to about 157.60 yen per dollar.
- How Would US-China Relations Look if Trump's Party Loses Congress?
Results of the US midterm elections could shift the balance of power in Congress, but the Democrats' immediate priorities are likely to be investigating the current administration and checking President Donald Trump's executive power. Chen Dongxiao, president of the Shanghai Institutes for International Studies, told The Paper that the vote is unlikely to cause major disruption to US-China ties, since the president retains considerable autonomy in foreign policy and both parties largely agree on China strategy. Two issues could add strain: Taiwan, where lawmakers have long been unhappy with Trump's delays in approving arms sales to Taipei, and AI, where competition and cooperation can coexist as both sides seek advantage while managing global security risks. Despite positive signals, including friendly personal ties between Trump and Xi during the September Washington visit, distrust and rivalry for power remain key challenges.
- From 1 January 2027, Regional Minimum Wages Rise; Employers May Not Cut Allowances to Offset Pay
Decree 399/2026/NĐ-CP, effective 1 January 2027, sets monthly minimum wages for employees on labour contracts at VND 5.7 million in Region I, VND 5.08 million in Region II, VND 4.45 million in Region III and VND 4.04 million in Region IV. Employers must review labour contracts, collective labour agreements and internal regulations and adjust them accordingly, and may not abolish or reduce pay entitlements for overtime, night work or in-kind meal allowances. Existing agreements that are more favourable to workers, such as pay for jobs requiring training at least 7% above the minimum wage or arduous, hazardous work at least 5% higher, continue to apply unless the parties agree otherwise. Pay under weekly, daily, piece-rate or contract arrangements, when converted to monthly or hourly terms, also cannot fall below the corresponding minimum.
- Novo Resources expands high-grade gold search - ICYMI
Novo Resources (TSX:NVO, ASX:NVO) is set to begin a 2,700-metre reverse circulation (RC) drilling program at the Clone prospect within its Tibooburra Gold Project in New South Wales, targeting extensions of high-grade gold mineralisation. The campaign follows up on 2025 drilling that returned 12 metres at 5.9 grams per tonne gold from near surface, and will focus on tracking the mineralised system to the north and testing its down-plunge continuation at depth. The broader Albert Goldfield spans about 30 kilometres of strike, but much of it has seen little modern exploration, and faulting and cross-cutting structures also need to be understood. Novo holds 70% of a joint venture with Manhattan Gold Corporation Ltd, where it is operator, and is running regional stream sediment, rock-chip and soil sampling to identify new drill targets for 2027.
- USD Price Drops Close to VND 25,900
Bank dollar rates kept falling through the past week, reaching their lowest level in about a year and a half on the morning of 4 November, with Vietcombank quoting VND 25,520–25,930 per USD. The State Bank of Vietnam set the central rate at 25,267 dong per dollar, down 3 dong, and commercial banks may trade within a 5% band. Over the week the dollar fell nearly 100 dong (0.35%) and about 1.7% since the start of the year, while the US Dollar Index dropped nearly 0.9% to around 101.3 points. Techcombank expects USD/VND to hover near 26,000, supported by an interest rate gap of over 3 percentage points and record FDI disbursement of USD 21.1 billion in the first nine months, up 12%.
- ZachXBT identifies French bank as alleged victim of $133M crypto theft
Onchain investigator ZachXBT has identified French banking group Crédit Mutuel Arkéa as the alleged victim of a crypto theft exceeding $133 million, and warned the total could be higher because some OTC transactions may not be counted. The bank's involvement has not been independently verified or confirmed by the bank, which did not respond to Cointelegraph's request for comment. ZachXBT first flagged over $106 million in suspicious withdrawals from centralized exchanges on Monday, then raised the estimate after another $27 million surfaced on Tuesday. Blockchain analytics firm Bitquery traced about $63 million in stablecoins converted into Ether within four hours, and Kraken and Crypto.com said they had restricted accounts or blocked related funds, stating their platforms remained secure.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.